Corporate Profile
Taxus Cardium Pharmaceuticals is an advanced regenerative therapeutics company that is focused on the late-stage clinical and commercial development of regenerative medicine therapeutics including Generx®, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of Cardiac Microvascular Insufficiency due to advancing coronary artery disease, and Excellagen®, an FDA-cleared acellular biological skin substitute designed as a professional-use advanced wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers, which also has multiple additional potential tissue regeneration applications based on stem cells and other biologics.
Stock Quote
CRXM (Common)
ExchangeOTC BB (US Dollar)
Price$0.47
Change (%) Stock is Down 0.02 (4.08%)
Volume17,658
Data as of 05/27/15 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock Chart
Stock chart for: 03NA000000CRXM
Recent News
DateTitle 
05/26/15Angionetics To Present At 2015 LD Micro Invitational Investor Conference On Business And Generx® Phase 3 Clinical Development ActivitiesPrinter Friendly Version
05/15/15Angionetics Presents at the 2015 American Society of Gene & Cell Therapy Conference On Generx® Angiogenic Phase 3 Gene Therapy ProgramPrinter Friendly Version
05/11/15Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx® Clinical Development ActivitiesPrinter Friendly Version
04/13/15Angionetics Initial Equity Funding to Advance as Independent Company to Develop and Commercialize Phase 3 Generx® Gene Therapy Product CandidatePrinter Friendly Version
Primary IR Contact
Shareholder Services
Corporate Communications/Investor Relations
11750 Sorrento Valley Road
San Diego, CA 92121

Phone: 858-436-1018
E-mail: investorrelations@cardiumthx.com


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.